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ABSTRACT
The interaction disorder between gut microbiota and its host has been documented in different 
non-communicable diseases (NCDs) such as metabolic syndrome, neurodegenerative disease, and 
autoimmune disease. The majority of these altered interactions arise through metabolic cross-talk 
between gut microbiota and host immune system, inducing a low-grade chronic inflammation that 
characterizes all NCDs. In this review, we discuss the contribution of bacterial metabolites to 
immune signaling pathways involved in NCDs. We then review recent advances that aid to 
rationally design microbial therapeutics. A deeper understanding of these intersections between 
host and gut microbiota metabolism using metabolomics-based system biology platform promises 
to reveal the fundamental mechanisms that drive metabolic predispositions to disease and suggest 
new avenues to use microbial therapeutic opportunities for NCDs treatment and prevention.
Abbreviations: NCDs: non-communicable disease, IBD: inflammatory bowel disease, IL: interleukin, 
T2D: type 2 diabetes, SCFAs: short-chain fatty acids, HDAC: histone deacetylases, GPCR: G-protein 
coupled receptors, 5-HT: 5-hydroxytryptamine receptor signaling, DCs: dendritic cells, IECs: intest-
inal epithelial cells, T-reg: T regulatory cell, NF-κB: nuclear factor κB, TNF-α: tumor necrosis factor 
alpha, Th: T helper cell, CNS: central nervous system, ECs: enterochromaffin cells, NSAIDs: non- 
steroidal anti-inflammatory drugs, AhR: aryl hydrocarbon receptor, IDO: indoleamine 2,3-dioxygen-
ase, QUIN: quinolinic acid, PC: phosphatidylcholine, TMA: trimethylamine, TMAO: trimethylamine 
N-oxide, CVD: cardiovascular disease, NASH: nonalcoholic steatohepatitis, BAs: bile acids, FXR: 
farnesoid X receptor, CDCA: chenodeoxycholic acid, DCA: deoxycholic acid, LCA: lithocholic acid, 
UDCA: ursodeoxycholic acid, CB: cannabinoid receptor, COBRA: constraint-based reconstruction 
and analysis
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In the past century, a disturbing trend has been 
the consistent rise in non-communicable dis-
eases (NCDs) which currently represent 70% of 
global mortality.1 NCDs are chronic diseases 
that have in common an underlying low-grade 
inflammation. These include early-onset NCDs, 
such as allergies, asthma, and some autoimmune 
diseases, and later-onset NCDs, including cardi-
ovascular disease (CVD), metabolic syndrome, 
and neurodegenerative disorders.1,2 Under 
normal conditions, inflammation induces 
a physiological response to keep homeostatic 
balance within tissues. However, the chronic 
inflammatory states that are observed in NCDs 
do not appear to fit this model as tissues adapt 
to new physiological or metabolic conditions. 
Although inflammation and the pathways to dis-
ease are multifactorial, extensive application of 
next-generation sequencing and gnotobiotics 
technologies (germ-free conditions or when 
inoculated with known microorganisms) have 
revealed increased implication of altered gut 
colonization patterns (dysbiosis) in the physio-
logic, immunologic, and metabolic dysregula-
tion, seen in a myriad of NCDs (Table 1). 22,23 
For example, gut metagenomic profiles of 
patients with inflammatory bowel disease (IBD) 
are highly correlated with fecal calprotectin 
levels, a biomarker for severity of inflammation 
in IBD.15 Moreover, a significant correlation 
between gut microbiota dysbiosis and an 
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elevated level of interleukin 6 (IL-6) was found 
in plasma samples of patients with type 2 dia-
betes (T2D).24
The human gut is a diverse niche which hosts 
hundreds of species of commensal bacteria, proto-
zoa, and fungi that live in a symbiotic relationship 
with their host and has a wide-ranging impact on 
host physiology.25 Accordingly, the preservation of 
beneficial interactions between the host and its gut 
microbiota is a key requirement for health. 
Although the enigmatic network of interactions is 
beginning to be unraveled, inflammation as 
a consequence of dysbiosis indicates the impor-
tance of immune signaling in communication 
between the host and gut microbiota.26 
Considering that the gut is the residence for up to 
80% of immune cells in the body and that micro-
biota contain nearly 150-fold more genes than the 
host genome, it is not surprising that bacterial 
metabolites play an important role in educating 
immune cells and modulating immune 
signals.27,28 Engagement of gut microbial metabo-
lites with host immune receptors both locally and 
on extra-intestinal organs form an extensive array 
of signals that respond to changes in the environ-
ment, nutrition, health, and immunological status. 
In turn, the immune system participates in shaping 
and preserving the ecology of the gut 
microbiota.28,29 Therefore, in individuals with dys-
biosis, disturbance of immune signaling pathways 
can lead to chronic, non-resolving inflammation, 
and tissue damage which has emerged as a common 
feature in NCDs.1
Despite a large amount of metagenomics data on 
the role of gut microbiota dysbiosis in the develop-
ment of NCDs, the underlying mechanisms in 
which bacterial metabolites influence the host 
immune system remain to be fully elucidated. 
A deeper understanding of the intersections 
between host and gut microbiota metabolism pro-
mises to reveal the fundamental mechanisms that 
drive metabolic predispositions to disease and 
might suggest new metabolite-based therapeutic 
opportunities for NCDs. Mechanistic models that 
predict the potential of individual microbes to pro-
cess certain metabolites could aid in revealing 
microbe-metabolite-receptor associations and 
improve our understanding of the effect of 
a specific microbial community on the metabolome 
and immune signaling. In this review, we provide 
an overview of gut bacterial metabolites in NCDs 
with a physiological effect on major immune func-
tions. We then review recent advances that help our 
ability to rationally design microbial therapeutics.
Microbiota and gut metabolites
One of the essential functions of the gut micro-
biota comprises the modulation of gastrointest-
inal metabolites, including their synthesis, 
digestion, fermentation, and secondary metabo-
lism. It has been estimated that over 8000 non- 
nutritious compounds (such as dietary fiber and 
polyphenols that are not classified within the 
six basic nutrient groups) are present in the 
human gut, of which most compounds are not 
digested by human digestive enzymes.30 
Macronutrients (lipids, carbohydrate and pro-
teins) and complex dietary fibers that reach the 
colon, undergo microbial fermentation and cat-
abolism, resulting in the production of essential 
metabolites such as short-chain fatty acids 
(SCFAs), essential amino acids, vitamins, and 
hormones. Although the colon is the major 
site of this fermentation, the microbiota at 
other sites, such as small intestine (mainly lac-
tobacilli and streptococci), contribute to regula-
tion of nutrient absorption and metabolism 
conducted by the host.31 In gut microbiota 
dysbiosis, numerous of microbial metabolites 
are altered. According to the type and concen-
tration of metabolites, host sensing receptors 
respond.32 In the following sections, we will 
highlight key examples of gut bacterial metabo-
lites and how these metabolite shifts contribute 
to the downstream modulation of host immu-
nity and chronic inflammation in NCDs.
Short-chain fatty acids
SCFAs are among the well-studied metabolites 
because of their important role in human 
health.33 SCFAs (mainly butyrate, propionate, 
and acetate) are present in high concentrations 
(20–140 mM per day depending on the diet) in 
the human cecum and the ascending and trans-
verse colon as end products of bacterial fermen-
tation of dietary fiber.28,34,35 Due to the lack of 
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polysaccharide lyase enzymes in humans, undi-
gested dietary fiber reaches the colon where it 
undergoes a two-stage degradation. The degra-
dation is done mainly by bacterial genera such 
as Bacteroides, Clostridium, Bifidobacterium, 
Prevotella, and Ruminococcus.35 In addition to 
their role as an important energy source (have 
been extensively reviewed elsewhere36,37), SCFAs 
are involved in a broad array of double-faced 
functions that influence both host immune sig-
naling and the commensal microbial 
community.33,38 A considerable amount of stu-
dies highlight the importance of SCFAs for 
immune system functioning. For instance, 
Nagpal et al.39 showed that application of infant 
gut-origin Lactobacillus and Enterococcus strains 
increase the level of SCFAs in feces and moder-
ate the gut microbiota perturbation resulting in 
a reduction of inflammation in both mouse and 
human models. Furthermore, they revealed that 
the antagonistic activity of these strains against 
clinical isolates of uropathogenic E. coli and 
Klebsiella pneumonia was due to the production 
of SCFAs.
SCFAs can modulate immune cells by affecting 
their cytolytic activity, cytokine production, and 
regulation of gene expression.40 The anti- 
inflammatory effect of SCFAs are mediated through 
two major signaling pathways: 1) inhibition of his-
tone deacetylases (HDAC), and 2) activation of 
G-protein-coupled receptor signaling (GPCR) 
(Figure 1). 26,33
(1) HDAC inhibition
HDAC activity can decrease histone acetylation 
and thereby modulate gene expression in a variety 
of cells. Inhibition of HDAC can result in 
increased expression of some genes, but may at 
the same time induce acetylation of some tran-
scription factors and further suppression of the 
transcription process.41 As an HDAC inhibitor, 
SCFAs can inhibit inflammation by suppressing 
the expression of the pro-inflammatory cytokines 
interleukin 6 (IL-6) and IL-12 in various immune 
cells such as local macrophages and dendritic cells 
(DCs).26 IL-6 is among the major factors that 
mediate inflammation into its chronic phase. 
Elevated levels of IL-6 in the brain have been 
observed in different neurodegenerative diseases 
such as multiple sclerosis, Parkinson’s and 
Alzheimer’s disease.42 An increased plasma level 
of IL-6 has also been reported in patients with 
T2D, which was in conjunction by a prevalence 
of Prevotella copri and Bacteroides vulgatus in 
their feces.24 Butyrate is able to regulate the trans-
forming growth factor β promoter in intestinal 
epithelial cells (IECs) in an HDAC-dependent 
manner leading to the accumulation of 
T-regulatory (T-reg) cells in the gut.43 Colonic 
T-reg cells are critical for limiting intestinal 
inflammation. Interestingly, a beneficial effect of 
butyrate is associated with a reduction of nuclear 
factor κB (NF-κB) translocation in macrophages 
within the lamina propria of patients with Crohn’s 
disease.20
HDAC inhibition by SCFAs is not restricted to 
immune cells in the gut. SCFAs can be transported 
across the gut epithelium into the circulation, 
affecting distant organs. For instance, exposure of 
peripheral blood mononuclear cells and neutro-
phils to SCFAs in vitro can reduce NF-κB activity 
via HDAC inhibition and thereby down-regulate 
production of the pro-inflammatory cytokine 
tumor necrosis factor alpha (TNF-α).35 In the 
lungs, acetate and propionate control the hyperac-
tivity of airways by inhibiting HDAC and reducing 
the action of T helper cell (Th-2) by increasing DC 
proliferation.18 Maternal acetate during pregnancy 
can protect the offspring against allergic airway 
disease,44 whereas HDAC inhibitors such as 
sodium butyrate markedly inhibit brain microglia- 
induced inflammation.45 Thus, the HDAC pathway 
actively contributes to the maintenance of immu-
nological tolerance and control of pro- 
inflammatory cytokines.
(1) GPCR activation
GPCRs are one of the largest and most diverse 
families of integral membrane protein receptors in 
mammalian genomes. Many signaling pathways in 
the human body rely on this family of receptors and 
therefore play an important role in medicine and 
drug development.46 A high presence of GPCRs is 
found within the gastrointestinal tract (mainly 
GPCR41, GPCR43, and GPCR109), emphasizing 
the importance of this receptor family for the 
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regulation of host-microbial interactions.47 
Butyrate can bind GPCR109 on epithelial cells, 
macrophages, and DCs and trigger the secretion 
of IL-18 and IL-10, which further leads to suppres-
sion of inflammation. Deficiency of IL-10 in human 
and animal models leads to intestinal inflammation 
and the growth of enteric pathogens which can 
promote the development of colorectal cancer.46 
GPCR43 is present in different tissues such as adi-
pose tissue and gastrointestinal cells, with the high-
est expression found in immune cells.48 Recent 
evidence indicates that a high-fiber diet activates 
GPCR43 on IECs, which results in activation and 
assembly of the inflammasome, a protein complex 
that enables maturation of the pro-inflammatory 
cytokines by caspase-1-mediated cleavage. 
Formation of inflammasomes leads to downstream 
production of IL-18, a key cytokine for the repair 
and maintenance of the epithelial integrity.49 
However, in the context of colitis, ambivalent 
results have been published, which presents 
a possible dual role of SCFAs and GPCR43 in con-
trolling inflammation.50 This explains the impor-
tance of cell types and their location for the 
downstream activation of GPR43.
The interaction of SCFAs with GPCRs are not 
limited to the gut. Maturation and proper function-
ing of murine microglia in the central nervous 
system (CNS) is dependent on SCFAs and 
GPCR43.51 Moreover, activation of GPCR41 in 
enteric nerves, mainly by butyrate and propionate, 
indicates that SCFAs signaling may be transferred 
directly to the nervous system.52 Activation of 
GPCR41 signaling by SCFAs was also shown to 
protect against allergic airway disease by reducing 
Th2 cell activity in the lungs.18 Although SCFA- 
mediated GPCR signaling has been shown to play 
an important role in modulating the host immune 
system, it remains an extremely complex process 
which is still at an early stage of investigation.
Preclinical animal studies suggest that SCFAs can 
influence gastrointestinal motility. Immune cells 
express a wide range of GPCRs as neurotransmitter 
receptors, which can respond to serotonin modula-
tion. Enterochromaffin cells (ECs) are a type of che-
mosensory cells within the gut epithelium and are 
involved in neural monitoring of the gut. ECs can 
affect gastrointestinal motility and secretion through 
serotonin production.28 ECs synthesize more than 
90% of the serotonin in the human body. SCFAs can 
promote the production of serotonin in the enteric 
nervous system via GPCR 43 and GPCR 41, and affect 
gut motility through 5-HT signaling (5-hydroxytryp-
tamine receptor signaling). Moreover, blocking 5-HT 
signaling results in bacterial translocation across the 
intestinal barrier and inflammation.27 Gastrointestinal 
motility disorders are frequent in patients with 
Parkinson’s disease, multiple sclerosis, IBD.53–55
Another way in which SCFAs affect the immune 
system is epigenetic regulation of gene expression. 
One such example is the butyrate-induced up- 
regulation of muc genes and mucus secretion in goblet 
cells, which is essential for mucosal immunity and 
gastrointestinal integrity.56
Although many studies discussed the importance of 
SCFAs for human health, the interaction between 
Figure 1. Immune signaling pathway activated by Short-Chain Fatty Acids. SCFAs act on immune cells mainly through two pathways: 
activation of G-protein coupled receptors (GPCRs) such as GPCR 41, GPCR 43, and GPCR 109 and inhibition of histone deacetylase 
(HDAC). AC: acetylate; HAT: histone acetylase.
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SCFAs and their receptors might not always be bene-
ficial to the host. For instance, butyrate induced aber-
rant proliferation and transformation of colon 
epithelial cells in a genetically susceptible mouse 
model of colorectal cancer.57 Moreover, SCFAs can 
aggravate neutrophilic inflammatory response, pro-
moting the outgrowth of Pseudomonas aeruginosa in 
patients with cystic fibrosis.58 Therefore, further 
research on the immunomodulatory effects of 
SCFAs based on concentration and target cells is 
warranted.
In addition to modulating the immune system, 
SCFAs can be important in gut bacterial commu-
nication. A low fiber and/or high-fat diet can 
remarkably reduce gut microbiota diversity, exem-
plified by abnormally high Firmicutes and low 
Bacteroidetes abundances in multiple NCDs.59 
Inoculation of SCFAs producing bacteria can 
increase Bacteroidetes abundances while reducing 
Firmicutes, and improve balance in the gut bacter-
ial structure.34
Overall, these data have led to emerging interests 
in the regulatory function of SCFAs in a wide range 
of immune cells, including both innate and adap-
tive cells. The effect of SCFAs, whether on the 
immune system or gut microbial community, is 
concentration-dependent and the favorable normal 
physiological range needs further research, as dis-
cussed below. Understanding the interaction of 
SCFAs with their receptors in detail might provide 
great insights into the development of new thera-
peutic avenues to treating NCDs patients through 
dietary manipulation.
Indole and indole acid derivatives
Amino acid metabolism has an important impact 
on immune cell function. Although endogenous 
metabolism of amino acids by human play impor-
tant roles in regulating gut immune function, the 
potential contribution of resident microbiota 
should not be ignored. Amino acids that reach the 
lower part of the gut are transformed by specific 
bacteria, resulting in the production of specific 
amino acids with signaling properties. The most 
abundant amino acid fermenting bacteria in 
humans belong to the Clostridium clusters, the 
Bacillus-Lactobacillus-Streptococcus groups, and 
Proteobacteria.60
L-tryptophan is an aromatic amino acid com-
posed of a β carbon connected to the 3-position of 
an indole group. In the human body, several signal-
ing molecules are derived from tryptophan through 
three major pathways: kynurenine pathway, the 
serotonin pathway or direct transformation to dif-
ferent indole derivatives compounds such as tryp-
tamine, indole and its derivatives.28,61,62 The 
physiological effect of compounds derived from 
tryptophan metabolism can be either protective or 
detrimental depending on the signaling pathway 
and target tissue involved (Figure 2).
Indole is one of the major products of bacterial 
tryptophan metabolism. It has been detected in 
different concentrations (0.25–1.1 mM) in feces of 
healthy individuals, while a significant decrease 
(3.5 × 10−7 – 0.00110 μM/g feces) has been reported 
in different NCDs such as IBD, autoimmunity, 
neurodegeneration and diabetes.28,63,64 Exposure 
of human colon-cancer cell line to 1 mM indole 
in vitro could inhibit inflammation by up- 
regulating the expression of the anti-inflammatory 
cytokine IL-10, decreasing TNF-α-mediated activa-
tion of NF-κB, and expression of the pro- 
inflammatory chemokine IL-8.65 Furthermore, 
indole promotes epithelial barrier functions of 
intestinal cells by inducing increased expression of 
tight junction proteins between cells, thereby con-
tributing to trans epithelial resistance to 
inflammation.62 Additionally, indole administra-
tion attenuated multiple deleterious effects of non- 
steroidal anti-inflammatory drugs (NSAIDs) on the 
gut in a murine model of NSAID enteropathy, by 
modulating neutrophilic inflammation and altering 
the gut microbiota composition and diversity.66 
Together, these studies highlight the anti- 
inflammatory and beneficial effects of indole on 
intestinal health.
Indole-3-aldehyde and indole-3-propionic acid 
are indole derivatives that can act as ligands for 
the aryl hydrocarbon receptor (AhR).67 AhR is 
a member of the ligand-activated transcription fac-
tor family on epithelial and immune cells and 
a powerful modulator of immune cell 
proliferation.9 Zelante et al.61 showed that produc-
tion of Indole-3-aldehyde by a subset of commensal 
lactobacilli in small intestine such as L. reuteri and 
L. johnsonii activate innate lymphoid cells to release 
IL-22, resulting in secretion of anti-microbial 
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peptides by epithelial cells, mucosal protection 
from inflammation, and fortification of epithelial 
cell tight junctions. In mouse models, decrement of 
the gut microbiota using the antibiotic ampicillin 
decreased the levels of the AhR agonist indoxyl- 
3-sulfate and worsened autoimmune encephalo-
myelitis disease scores.68 In human astrocytes, 
indoxyl-3-sulfate treatment reduces the expression 
of pro-inflammatory factors such as TNF- α and IL- 
6. Supplementation with the tryptophan metabo-
lites indoxyl-3-sulfate, indole-3-propionic acid and 
indole-3-aldehyde was successful in reducing CNS 
inflammation through AhR in autoimmune ence-
phalitis mouse models.61 Moreover, a recent study 
by Ageuro et al.69 indicated that indole derivatives 
from gestationally-colonized maternal microbiota 
increased mononuclear phagocytes in their 
offspring.
Skatole (3-methylindole) is another indole- 
derived metabolite that occurs naturally in feces. 
The fecal skatole concentration can vary consider-
ably between individuals and may indicate different 
health states.65 Fecal skatole levels in healthy indi-
viduals are usually ~5 μg/g feces, whereas fecal 
skatole levels may increase up to 80–100 μg/g 
feces in persons who suffer from disturbed intest-
inal microbiota, such as patients with colorectal and 
colon cancer.70 Despite little information is avail-
able on the role of skatole in immune signaling, an 
elevated level in inflammation may highlight the 
importance of further studies.
The tryptophan-derived monoamines, trypta-
mine, and serotonin, stimulate gut peristalsis by 
signaling through the serotonin receptors in the 
gut, as discussed above.
Tryptophan metabolism through the kynurenine 
pathway is mediated by either indoleamine 
2,3-dioxygenase (IDO) or tryptophan 2,3-dioxy-
genase which leads to the production of kynurenine 
and downstream products, such as kynurenic acid 
and quinolinic acid (QUIN). The gut microbiota is 
known for its contribution to the kynurenine path-
way by regulating IDO 1 expression.61,71 Although 
IDO-dependent tryptophan metabolism plays 
a minor role under normal conditions, it is strongly 
upregulated in response to inflammatory factors 
(e.g., interferon gamma, TNF-α and NF-κB).17,72 
Overexpression of IDO 1 and increased QUIN 
levels have been reported in IBD patients and dif-
ferent neurological disorders such as Alzheimer’s 
disease, anxiety, depression, epilepsy and human 
immunodeficiency virus-associated neurocognitive 
disorders.73 Gut bacteria such as Lactobacillus spp., 
Pseudomonas aeruginosa, Pseudomonas fluorescens 
Figure 2. Overview of the different ways microbes degrade tryptophan in the human gut. Tryptophan metabolites regulate various 
host processes through their function as signaling molecules. In the gut, tryptophan can undergo several possible chemical alterations: 
the direct transformation of tryptophan by the gut microbiota into several molecules, such as indole and its derivatives, and indirectly 
through the kynurenine pathway and the serotonin pathway. Various tryptophan catabolites are ligands for the aryl hydrocarbon 
receptor (AhR) expressed on intestinal immune cells and thereby alter innate and adaptive immune responses. AhR ligands are 
denoted with a red asterisk. Pro-inflammatory factors (NF-κB, TNF-α and interferon gamma) upregulate indoleamine 2,3-dioxygenase 
(IDO) expression, whereas anti-inflammatory factors such as IL-4 inhibit its expression. IDP: indole propionic acid; IDS, indoxyl sulfate, 
IDA: indoxyl acetic acid.
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possess the enzyme aspartate aminotransferase, and 
produce kynurenic acid by transamination of 
kynurenine.72 Increased level of kynurenic acid 
has been reported in patients suffering from IBD, 
T2D, and multiple sclerosis.74 Kynurenic acid can 
modulate the intestinal inflammation and limit 
inflammation-induced cell damage in CNS through 
GPCR35 and AhR mediated signals. Moreover, 
kynurenic acid can increase energy expenditure by 
activating GPCR35, which stimulates lipid metabo-
lism and anti-inflammatory phenotype in adipose 
tissue.75
As yet, the characterization of tryptophan- 
metabolizing organisms, together with their asso-
ciated biochemical pathways, remains an indispen-
sable challenge. Development of high-throughput 
and high-sensitivity methods, as well as the integra-
tion of multi-omics modalities, offer promising 
strategies to identify the variety of microorganisms 
and microbial genes involved in the modulation of 
tryptophan metabolism.
Choline
Choline is an essential dietary nutrient for humans 
and is required for the synthesis of the neurotrans-
mitter acetylcholine, the membrane lipid phospha-
tidylcholine (PC) and sphingomyelin, and the 
methyl donor glycine betaine. Previous work unra-
veled a critical role for gut microorganisms 
(Firmicutes; especially the Clostridium cluster 
XIVa and Eubacterium, Actinobacteria and 
Proteobacteria) in the degradation of choline to 
trimethylamine (TMA), which is further metabo-
lized in the liver to trimethylamine N-oxide 
(TMAO). Systemic concentration of TMAO in nor-
mal healthy individuals ranges from 0.5 to 5 μM 
and can vary greatly after the intake of certain 
foods.76,77
It is important to highlight that less than 1% of 
the gut microbiota harbor the genes required for 
TMA production. Nevertheless, even very low con-
centrations of these gut bacteria seem to be suffi-
cient for TMA production, which illustrates the 
importance of the gut microbiota in this context. 
Recently, Chittim et al.78 explored the origin of the 
choline metabolized by the gut microbiota and dis-
covered that choline-utilizing gut microorganisms 
can hydrolyze PC using a phospholipase D enzyme 
and further convert the released choline to TMA. 
This finding provides novel opportunities for treat-
ing TMA-related pathologies, as altered plasma 
levels of TMAO have been implicated in 
a number of adverse host pathologies, including 
CVD, nonalcoholic steatohepatitis (NASH), IBD 
and CNS disorders. Choline-deficient diets and 
subsequent low serum TMAO levels have been 
associated with NASH, by reducing the microbiota 
diversity and inducing intestinal dysbiosis. For 
instance, choline deficient diets induced 
a remarkable decrease in abundance of amongst 
others Bifidobacteria and Lactobacilli, whereas 
microbial clades such as Bacteriodetes, 
Ruminococus and Firmicutes were increased.79,80 It 
is suggested that this dysregulation in the micro-
biota promotes NASH development by activating 
the inflammasome, as inflammasome activity is 
involved in formation of fibrotic plaques in NASH 
pathology.81 These data indicate that choline is 
necessary for maintaining a healthy gut microbiota. 
Moreover, choline has been shown to exert anti- 
inflammatory effects. For example, in asthma 
patients, supplementation of choline significantly 
reduced IL-4, IL-5,TNF-α, leukotriene and total 
IgE levels as compared to baseline.82 Conversely, 
high concentrations of choline and the resulting 
elevation in TMAO plasma levels have been asso-
ciated with increases in abundancy of TMA- 
producing bacteria (e.g. Clostridiaceae and 
Coriobacteriaceae) and the development of CVD 
and neurological disorders.
One of the mechanisms through which TMAO 
induces low-grade inflammation is the activation of 
NF-κB signaling. Seldin et al.83 demonstrated that 
Ldlr−/− mice fed a choline-rich diet showed ele-
vated TMAO levels and a consequent increase in 
expression of pro-inflammatory genes including 
pro-inflammatory cytokines, adhesion molecules 
and chemokines in the aortic endothelium and 
smooth muscle cells. Through pharmacological 
inhibition, they showed that NF-κB and GPCR 
signaling are required for TMAO to exert pro- 
inflammatory effects on endothelial cells.
Another way through which TMAO exerts pro- 
inflammatory effects is activation of the inflamma-
some. In colon epithelial cells, TMAO was shown 
to trigger activation of the inflammasome and pro-
duction of reactive oxygen species in a dose- and 
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time-dependent manner, suggesting a potential role 
for TMAO in IBD pathogenesis.21 However, more 
research is needed in this context, as Wilson and 
colleagues found lower TMAO levels in IBD 
patients compared with healthy individuals.84 
Similarly, they reported lower TMAO levels in 
patients with active UC compared to individuals 
with the inactive form of the disease.
Although the role of TMAO in the CNS has yet 
to be fully explored, it has recently been shown that 
TMAO can be detected in human cerebrospinal 
fluid. In addition, recent findings in mouse models 
have reported that TMAO promotes brain aging 
and cognitive impairment, as well as impaired long- 
term potentiation and synaptic plasticity in mice.85 
In mice, TMAO concentrations in plasma and the 
brain were shown to increase in parallel with aging, 
suggesting that TMAO crosses the blood-brain 
barrier.86 The increased concentration of TMAO 
in whole-brain lysates of old mice was associated 
with higher brain pro-inflammatory cytokines 
(IL1-β, IL6, and TNF-α), total NF-κB abundance, 
and markers of astrocyte activation in comparison 
with young adult mice. Old mice also tended to 
have (presumably compensatory) higher brain anti- 
inflammatory IL-10 compared to young mice.85
In conclusion, these data indicate a strong link 
between microbiota-dependent production of 
TMAO, inflammation and an increased risk of, 
among others, cardiovascular and neurological dis-
orders. Despite the overwhelming amount of evi-
dence demonstrating correlations between TMAO, 
inflammation and CVD, these correlations are yet 
to be (fully) explored in other NCDs.87
Bile acids
Bile acids (BAs) are a diverse group of amphipathic 
steroid acids derived from cholesterol in the liver.88 
Apart from their essential role in vitamin absorp-
tion, lipid absorption, and cholesterol homeostasis, 
BAs have recently been recognized as important 
signaling metabolites in the regulation of the 
immune system.28 Two major classes of BAs exist 
in mammals: primary and secondary. Whereas pri-
mary BAs are synthesized via cholesterol catabo-
lism in hepatocytes, secondary BAs are derivatives 
of primary BAs generated by microbial metabolism 
in the intestine.89 Primary BAs such as cholic acid 
and chenodeoxycholic acid (CDCA) are conjugated 
with glycine or taurine (in a lesser extent) in hepa-
tocytes before their secretion into the intestinal 
environment. Deconjugation of BAs in the distal 
small intestine and colon is carried out by bacteria 
with bile salt hydrolase (BSH) activity such as 
Lactobacillus, Bifidobacteria, Clostridium, and 
Bacteroides. Deconjugated BAs then undergo dif-
ferent microbial biotransformations such as dehy-
drogenation, dihydroxylation, and epimerization in 
the colon leading to more than 20 different second-
ary BAs.90,91
BAs are ligands for nuclear hormone receptors 
such as the farnesoid X receptor (FXR) and GPCRs, 
such as TGR5, which inhibit the induction of pro- 
inflammatory genes through inhibition of the NF- 
ƙB pathway.88,92 Secondary BAs such as deoxy-
cholic acid (DCA) and lithocholic acid (LCA) can 
suppress TNF-α production by macrophages via 
FXR. In the study by Renga et al.93 FXR−/− mice 
(FXR deficiency) exhibited an increase in colonic 
inflammation and cancer risk in comparison to the 
wild type. Guo et al.94 demonstrated that among 
BAs, secondary BAs (especially LCA) had the most 
potent effect on TGR5 signaling by inhibiting IL-1β 
production in macrophages. Clinical trials suggest 
that the elevated level of IL-1β in the circulation 
system is a risk factor for the development of T2D, 
and antagonism of IL-1β might be a promising 
treatment strategy. Moreover, secondary BAs can 
block the activation of the inflammasome.95 
Excessive activation of inflammasome has been 
reported in T2D, atherosclerosis, and Alzheimer’s 
disease.94
The effect of secondary BAs on the immune 
system depends on the type of secondary BAs, 
concentration, and the site of action. For example, 
a metagenomic study revealed that the abundance 
of BSH genes (bsh) was significantly reduced in the 
gut microbiome of a patient with IBD.96 These data 
are in line with previous evidence indicating 
increased fecal conjugated BAs and reduced sec-
ondary BAs in IBD patients.97 Inconsistent with 
these data are studies on Alzheimer’s disease, in 
which a reduction in primary BAs and an increase 
in secondary BAs was found in the serum of 
patients.98 Additionally, it was shown in a hepatic 
cancer mouse model that the capability of second-
ary BAs to down-regulate the expression of 
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chemokines was necessary for the accumulation of 
natural killer T cells. Inhibiting the accumulation of 
natural killer cells in the liver resulted in increased 
tumor growth.99 This inconsistency in the level of 
secondary BAs in different diseases might be the 
result of the activation of different BAs pathways.
Gut bacteria such as Ruminococcus can form 
ursodeoxycholic acid (UDCA), a secondary BA. 
UDCA can modulate the immune system through 
different mechanisms such as reduction of cytokine 
secretion by lymphocytes, immunoglobulin pro-
duction, and inhibition of eosinophil activation 
and degranulation. UDCA exerts anti- 
inflammatory effects in the lungs. In an asthma 
mouse model, UDCA reduced airway inflamma-
tion via DCs by secretion of IL-12. Moreover, 
UDCA has dose-dependent (50–200 µM) neuro-
protective effects by suppressing the NF-κB 
pathway.100 A growing number of pre-clinical and 
clinical studies underscore the potential benefit of 
UDCA in treatment of neurodegenerative 
diseases.101
The gut BAs pool modulates an important popu-
lation of colonic Treg cells, the generation of which 
is defined by the expression of the transcription 
factor Foxp3. Genetic abolition of BAs metabolic 
pathways in individual gut symbionts significantly 
reduced the number of Foxp3+ Tregs, whereas 
restoration of the BAs pool increased the levels of 
this Treg population and alleviated host suscept-
ibility to inflammatory colitis.102 Emerging studies 
have begun to unravel the molecular mechanisms 
underlying the regulation of colonic Tregs by the 
host-microbe biliary network. The secondary BA 
3β-hydroxydeoxycholic acid (isoDCA) has recently 
been shown to induce Foxp3 in DCs, thereby 
impairing their immunostimulatory properties. 
Ablation of FXR in DCs potentiated the generation 
of Treg cells and imposed a transcriptional profile 
similar to that induced by isoDCA, suggesting an 
interaction between this BA and nuclear 
receptor.103 In addition, a derivative of LCA, 
isoalloLCA, was shown to promote Treg differen-
tiation through the generation of mitochondrial 
reactive oxygen species, leading to increased 
Foxp3 expression.104
Overall, these data show that BAs have 
a pleiotropic signaling behavior in regulating the 
immune system and inflammation. Although much 
remains to be learned about the multifaceted func-
tions of BAs in vivo, existing data already paint 
a picture that BAs have an important and dynamic 
role in controlling inflammation in NCDs.
N-acyl amides
The interest in N-acyl amides has recently increased, 
especially with regard to their effect on the immune 
system. N-acyl amides such as N-arachidonoyl ethanol 
amide (anandamide), N-acyl glycine and N-acyl 
gamma amino butyric acid (N-acyl GABA) constitute 
an important family of endogenous lipid signaling 
molecules that are composed of a long-chain fatty 
acid connected to amino acids by an amide bond. 
N-acyl amides have similar effect on endogenous 
endocannabinoid receptors and are therefore consid-
ered as endocannabinoid analogs.105 In the last dec-
ades, research shed light on the importance of the 
endocannabinoid network in human physiology. 
The role of endocannabinoids in immune hemostasis 
has been hypothesized in different studies.106,107 
However, the function of the endocannabinoid recep-
tors on immune cells needs yet to be fully defined 
mechanistically. Endocannabinoids exert their actions 
mainly through GPCRs such as GPCR119, cannabi-
noid receptor (CB) 1, and CB2.105,107 They modulate 
T- and B-lymphocyte proliferation, macrophage- 
mediated killing of sensitized cells, inflammatory cyto-
kine production, immune cell activation by inflamma-
tory stimuli, chemotaxis, and inflammatory cell 
migration.92 However, there are a number of studies 
that show the double-edged sword effect of endocan-
nabinoids as both inhibitor and stimulator of the 
immune system.106 For example, some preclinical 
studies revealed that the activation of CB1 might 
lead to CNS inflammation in neurodegenerative 
diseases.108 By contrast, some other studies showed 
that over-activation of CB1 contributes to symptom 
progression in Alzheimer’s disease and T2D.109,110 
Hence, the effect of endocannabinoids may depend 
on different factors such as their concentration, target 
cells, and cellular environment.111 Gut microbiota can 
produce a large and diverse class of long-chain N-acyl 
amides that interact with endocannabinoid receptors, 
especially at the intestinal mucosa. Aguilera et al.112 
showed that gut microbiota dysbiosis upregulated 
CB2 expression, which was positively correlated with 
Lactobacillus spp. counts and negatively correlated 
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with Clostridium spp. counts. Moreover, a decreased 
amount of Akkermansia muciniphila has been 
reported in T2D patients (Table 1). Recently, it was 
shown that blocking CB1 ameliorates dysbiosis in 
T2D by increasing A. muciniphila abundance, which 
resulted in reduced inflammation.113 Cohen et al.105 
reported the presence of 143 unique n- acyl genes in 
the human gut microbiota. Their products were clas-
sified into six different families: long-chain N-acyl- 
glycine, lysine, glutamine, lysine/ornithine, alanine, 
and serinol. Among all, N -palmitoyl serinol has 
been found as the strongest agonist for GPCR119. 
N-acyl amides were shown to prevent the cytokine- 
induced increase in gut permeability in an animal 
model of multiple sclerosis.114 Another study revealed 
that prolonged antibiotic treatment resulted in low 
levels of N-acyl serotonin in the intestine, which sub-
sequently led to microglia inflammation and neuronal 
firing in depression mouse models.115 The mechanism 
of how gut dysbiosis affects the endocannabinoid net-
work remains to be established. Future studies are 
required to spell out the distribution and concentra-
tion of these metabolites throughout the gastrointest-
inal tract.
In summary, the structural similarities of micro-
biota-encoded N-acyl amides and endogenous 
endocannabinoids suggest that gut microbiota 
might communicate with their host using the 
same chemical language. Production of diverse 
N-acyl amides by gut microbiota introduces this 
community as a potential source for endocannabi-
noid-based therapies. On the other hand, a new 
challenge arises to endocannabinoid system-based 
drugs, since microbial N-acyl amides may interfere 
with the normal function of endogenous endocan-
nabinoid receptors and cause unwanted effects in 
non-target cells.116 As a dysregulated endocannabi-
noid network has been reported in different NCDs, 
understanding how gut microbiota contribute to 
this network is warranted and may suggest new 
therapeutic drugs for dysbiosis-related diseases.
Vitamins
Another category of bacterial metabolites that 
are essential for host metabolism are vitamins. 
Microbial fermentation and modulation are 
essential for acquiring vitamin B and vitamin 
Table 1. Impact of gut microbiota on immune system modulation in non-communicable diseases.




↑ Blautia, Bacteroides 
↓Firmicutes, Bifidobacterium, Dialister
5,6 
SCFAs, Serotonin, indole and indole acid 
derivatives 
Kynurenine, BAs, vitamin B
PD 3,7 
↑ Blautia, Ralstonia, Lactobacillus spp., Proteobacteria 




Kynurenine, BAs, vitamin B
MS 3,4 
↑ Pseudomonas, 
Mycoplana, Haemophilus, Blautia 
↓ Bacteroides, 
Faecalibacterium, 
Clostridia clusters XIVa and IV
5,9 
SCFAs, Serotonin, Kynurenine, 
indole acid derivatives, vitamin B
Metabolic syndrome Type II 
diabetes
10 
↑ Lactobacilllus spp., Bifidobacterium spp., Enterococcus 
spp. 











Allergic and immune 
disorders
IBD 15,16 
↑ Escherichia coli, Veillonella spp., Rumnicoccus spp. 
↓Faecailbacterium prausnitzii, Lactobacillus spp. 
Bifidobacterium spp.
15–17 
SCFAs, B vitamin, Bas, N1,N12-diacetylspermine, 
indole, Kynurenine
Asthma 18,19 
↑ Bacteroidetes, Clostridium difficile 
↓Bifidobacteria, Actinobacteria, Veillonella spp., 
Faecalibacterium, Rothia spp.
18,20,21 
SCFAs, BAs, phenolic acids
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K, as the host is not capable to perform the 
necessary biosynthetic reactions.40 The members 
of the vitamin K group are mainly vitamin K1 
(phylloquinone), and vitamin K2 (menaquinone) 
which are absorbed in the small intestine in 
a bile salt-, and pancreatic dependent 
solubilization.117 Vitamin K1 is obtained from 
ingested food and is mainly found in green 
leafy vegetables, while vitamin K2 is synthesized 
by certain intestinal bacteria, especially 
Enterobacter spp., Eggerthella lenta, Veillonella 
sp. and Bacteroides sp.118,119 Deficiency of vita-
min K2 has been reported in several diseases 
such as cardiovascular, and neurodegenerative 
diseases, and the bacterial flora composition is 
significantly altered in patients suffering from 
these diseases.120,121 Besides the well-known 
role in blood coagulation, preventing osteoporo-
sis and cardiovascular disease, recent studies 
indicate the significant effect of vitamin K on 
the immune system. Multiple studies showed 
that vitamin K2 is able to suppress the lipopoly-
saccharide-induced expression of inflammatory 
cytokines such as IL-6 by inhibiting the NF-κB 
pathway in vitro. Pan et al.122 showed that vita-
min K2 was able to dose-dependently (10–-
100 μM) inhibit TNF-α, IL-1 α, and IL-1 β 
gene expression in human monocyte-derived 
macrophages in vitro. Moreover, vitamin K was 
shown to exert a protective effect against colitis 
through downregulation of the pro- 
inflammatory cytokine IL-6 in mice fed with 
a vitamin K-supplemented diet.123
Group B vitamins consist of essential micronu-
trients that are involved in multiple physiological 
processes to maintain the body’s homeostasis, such 
as lipid metabolism, erythrocyte formation, and cell 
division amongst others. These are water-soluble 
vitamins that are acquired from dietary sources as 
well as from our commensal gut bacteria which are 
both consumers and producers of vitamins B.124 
Lactobacilli and Bifidobacterium are key producers 
of group B vitamins in the human intestine, being 
capable of synthesizing thiamine (B1), riboflavin 
(B2), niacin (B3), pantothenic acid (B5), pyridoxine 
(B6), biotin (B7), folate (B9), and cobalamin 
(B12).124 Recent studies indicate that B vitamins 
not only play an important role as cofactors and 
coenzymes in various metabolic pathways, but are 
also key to maintain immune homeostasis.117 
Vitamin B deficiency increases the risk of develop-
ing immune-related diseases by inhibition of lym-
phocyte proliferation and suppression of natural 
killer cell activity.125,126 Thus, the production of 
vitamin B by the gut microbiota is essential in 
modulating host immune function.
Niacin, i.e. vitamin B3, has been shown to ham-
per inflammation by inhibiting the production of 
the pro-inflammatory cytokines IL-1, IL-6, and 
TNF-α by macrophages and monocytes.127 This 
anti-inflammatory effect of niacin was confirmed 
by Singh et al.128 who found that ligation of 
GPCR109a by niacin suppressed colonic inflamma-
tion and carcinogenesis by inducing T-regulatory 
cell differentiation in mouse models. In contrast, 
vitamin B5 stimulates pro-inflammatory effects, 
resulting in IL-6 and TNF-α production by macro-
phages and corresponding Th1 and Th17 
responses.129 The mechanism underlying the regu-
lation of inflammation by pyridoxine, i.e., vitamin 
B6, remains to be elucidated. However, high levels 
of IL-4 have been reported in individuals with 
vitamin B6 deficiency, thereby increasing the risk 
of developing inflammatory diseases such as allergy 
and rheumatoid arthritis.130 Biotin, i.e., vitamin B7, 
exhibits anti-inflammatory effects by suppressing 
NF-κB expression through histone biotinylation. 
It thereby prevents the production of several proin-
flammatory cytokines such as TNF-α, IL-1, IL-6, 
and IL-8.131 Biotin deficiency has been reported in 
different diseases such as IBD and chronic alcohol-
ism. Suboptimal levels of biotin resulted in high 
levels of proinflammatory cytokines TNF-α, IL-1β, 
IL-12, and IL-23 in mouse models.132 As T-reg cells 
express high levels of folate receptor (folate recep-
tor 4 [FR4]) it is suggested that folate, i.e. vitamin 
B9, exerts anti-inflammatory effects. Decreased cell 
viability was observed in T-reg cells cultured under 
vitamin B9-reduced conditions, whereas an 
increased susceptibility to intestinal inflammation 
was found in mice fed with a folate-deficient diet.133 
At last, deficiency in cobalamin, i.e. vitamin B12, 
has been shown to decrease the number of CD8+ 
T cells and natural killer T cell activity in vitamin 
B12-deficient patients, whereas supplementation 
with methyl-cobalamin (known to be one of the 
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strongest immunomodulators among the vit.B12 
derivatives) ameliorated these conditions.134
Overall, vitamin K, as well as vitamin B, exert 
anti-inflammatory effects by downregulating the 
expression of pro-inflammatory genes. However, 
as is especially the case for vitamin B, the modula-
tion of the immune system is specific to different 
immune cells and immune responses, evidenced by 
the involvement of different B vitamins in regulat-
ing different immune signaling pathways. Since not 
all bacteria within the intestinal microbiome pos-
sess a complete vitamin B synthesis pathway, com-
petition may occur between the host and the 
intestinal microbiota for B vitamins as these bac-
teria utilize either dietary vitamin B or vitamin 
B produced by other bacteria. Research in this 
area remains challenging because vitamin- 
mediated regulation of immune homeostasis varies 
among individuals. This is not only due to inter- 
individual variability in gut microbiota composi-
tion but also due to the influence of poor dietary 
intake, nutrition and medication on intestinal 
microbiota diversity and functioning.
Polyamines
Polyamines are a class of ubiquitous low-molecular 
-weight organic cations that are essential in various 
cellular processes such as proliferation, differentia-
tion, and survival.135 Three polyamines, being 
putrescine, spermidine, and spermine, are part of 
the polyamine metabolic pathway that is critically 
regulated in a cell.136 Ingested food is the major 
source of polyamines in the upper parts of the 
intestine, from where they are transferred into the 
bloodstream via the colonic mucosa. As food- 
derived polyamines are absorbed before they 
reach the lower intestine, the gut microbiota is 
considered to be the major responsible cause of 
polyamine levels (0.5–1.0 mM) in the colon.137,138 
The most abundant polyamines produced by bac-
teria are putrescine and spermidine which are pre-
cursors for other polyamines such as spermine. 
Spermine inhibits the synthesis of the pro- 
inflammatory cytokines mainly TNF-α, IL-1, IL- 
12, and IL-6.139 Moreover, spermine administra-
tion suppresses the progression of experimental 
autoimmune encephalitis, a model for multiple 
sclerosis, by inhibiting the pro-inflammatory 
activity of macrophages.140 Spermidine inhibits 
LPS-induced inflammation by blocking the NF- 
κB, and MAPKs signaling pathways in microglia. 
Nitric oxide and prostaglandin E2 production were 
decreased in a dose-dependent manner, as well as 
the mRNA expression of pro-inflammatory cyto-
kines such as IL-6 and TNF-α.141 These data sug-
gest that polyamines exert anti-inflammatory 
effects resulting in amelioration of various disease 
states. Although polyamine metabolism generates 
pro-inflammatory cytotoxic products such as 
hydrogen peroxide, research indicates that polya-
mines have mostly anti-inflammatory effects.141
In contrast to healthy tissues, a dramatic increase 
in polyamine levels is observed within cancerous 
tissues, as the activity of the rate-limiting enzyme 
for polyamine synthesis (i.e., ornithine decarboxy-
lase) is upregulated by several oncogenic factors, 
including MYC family (regulatory gene and proto- 
oncogene).142 This allows the tumor cells to 
increase the uptake of polyamine from their micro-
environment and thereby promotes tumor survival 
mechanisms by suppressing tumor-specific 
immune responses. This was underscored by 
Hayes et al.,143 who showed that polyamine block-
ing therapy combined with inhibiting polyamine 
transporters reversed the immunosuppressive 
environment in multiple murine tumor models.
Taken together, these data suggest that polya-
mines can have harmful as well as beneficial effects 
on human health in different disease states. 
Strategies to regulate and optimize the concentra-
tions of polyamines in the intestinal tract are there-
fore likely to have practical applications.
Profiling biochemical activity
Overall, many of the bacterial metabolites men-
tioned in this review affect certain immune signal-
ing pathways such as NF-κB, which lead to down- 
or upregulation of pro-inflammatory factors 
(Figure 3). These effects make a ground for mod-
ulation of these immune pathways as a possible 
therapeutic target in NCDs. However, this review 
showed that unlike the involvement of certain 
receptors (e.g., HDACs, GPCRs, AHR and FXR), 
from a ligand point of view, a wide range of exo-
genous and endogenous metabolites can bind to 
these receptors and begin a cascade of immune 
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signaling, indicating that the signaling function of 
metabolites may be overlapping. Therefore, two 
important questions need to be answered prior to 
any microbiota- mediated and/or metabolic path-
way modulation.
1) How does modulation of metabolite concen-
tration initiate inflammation and at what point 
does it become detrimental?
2) In which pathways is the targeted metabolite 
involved and what will be the system-level effect of 
this modulation, including the effect on the gut 
microbial population?
Answering these questions necessitates deep 
insight into dynamic modulation of biological pro-
cesses. The power of metabolomics for dynamic 
measurement of phenotypes at the molecular level 
has brought this topic to the forefront of mechanistic 
discoveries related to pathophysiological processes. 
The recent advances in metabolomics methods such 
as untargeted metabolomics, isotope flux analysis, 
and high-resolution mass spectrometry techniques 
(liquid chromatography-mass spectrometry and gas 
chromatography-mass spectrometry) set the stage 
for more rigorous studies toward host-microbiota 
crosstalk.32,144
To fully comprehend causal interplay between 
the microbiota and the host immune system, 
a holistic understanding at all levels of the molecu-
lar architecture (genome, epigenome, transcrip-
tome, proteome and metabolome) is needed. This 
requires an approach to connect complex datasets 
into a comprehensive model that enables 
a systematic analysis of their interactions and can 
propose novel hypotheses. To achieve this, compu-
tational systems biology approaches that integrate 
the different data types into a network model are 
necessary.145 Metabolomics is therefore of emer-
ging interest for systems biologists as the metabo-
lome represents a direct readout of the biochemical 
activity of the individual,146 and is therefore the 
most predictive of phenotype. The main advantage 
of metabolomics in systems biology is the connec-
tion of metabolic networks to the underlying reac-
tion pathway structure thereby creating 
connectivity maps of pathways. Such reference 
map has recently been established for the human 
serum metabolome, in which potential determi-
nants of more than 800 metabolites could be pre-
dicted. Using machine-learning algorithms 
(gradient-boosted decision trees), researchers were 
able to predict circulating blood metabolite levels in 
a healthy human cohort of 491 individuals based on 
host genetics, gut microbiome, clinical parameters, 
diet, lifestyle and anthropometric measurements. 
Figure 3. Anti- inflammatory and pro-inflammatory immune modulation by bacterial metabolites. Microbial-associated metabolites 
affect multiple facets of the immune response such as neutrophil (NФ) chemotaxis and cytokine secretion by macrophages (MФ), 
dendritic cells (DC), and T-regulatory cells (T-reg). Based on the immune response, secreted cytokines can suppress or activate the NF- 
κB pathway. NF-κB is a major transcription factor that regulates expression of pro-inflammatory genes responsible for both the innate 
and adaptive immune response and inflammation such as TNF-α, IL-6, IL-8, and IL-1β.
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Metabolite levels were shown to be strongly affected 
by diet and microbiome, in some cases explaining 
more than 50% of the observed variance. Many of 
the associations and interactions found in this 
study could replicate previously reported findings, 
supporting the validity of this computational 
approach. The majority of them, however, are 
new, providing a useful resource for future 
research, either for unraveling a mechanistic 
understanding of alterations in metabolites under 
different conditions, or for designing interventions 
aimed at altering the levels of circulating 
metabolites.3
Thus, systems biology-based metabolome profil-
ing (Figure 4) can ultimately enable predictions of 
biomarkers and treatment response in 
a personalized manner and allow stratification of 
the patients as well as the proposition of potential 
novel therapeutic routes that can be validated 
experimentally and clinically.4,146 Systems biology 
approaches can be top-down or bottom-up. In the 
top-down approach, patterns and correlations are 
inferred from experimental data such as metabolo-
mics. In the bottom-up approach, predictive com-
putational models are generated by integrating 
different data types in a mechanistic manner.4 By 
integrating the microbiome, fecal metabolome, as 
well as microbial pathways and enzymes, links 
between microbial activity and changes in 
molecular architecture associated with NCDs (e.g., 
blood metabolome, transcriptome, proteome) 
could also be inferred. Integration of metabolomics 
with other -omics field such as metagenomics, tran-
scriptomics, proteomics and culturomics will 
thereby hopefully lead to the systematic prediction 
and discovery of host-microbe metabolic interac-
tions with a role in therapeutic outcomes.5
Using computer-guided design, Stein et al. have 
recently introduced a cocktail of 12 human-derived 
Clostridia as T-reg cell inducers due to their high 
SCFA outputs, which are currently undergoing 
clinical trials for the treatment of ulcerative 
colitis.39 Another study revealed a dysbiotic pattern 
in patients with Alzheimer’s diseases, while subjects 
without dementia or with other dementia types did 
not show this pattern.6 This pattern represented 
lower relative abundances of butyrate-producing 
species and higher relative abundances of taxa 
known to cause proinflammatory states in either 
neurological disorders or other colonic inflamma-
tory states. These important advances bridge pre-
vious microbiome association studies with NCDs 
toward causality by showing how the dysbiotic 
microbiota can potentially adversely affect home-
ostasis via dysregulation of immune signaling path-
ways. These promising strategies are indispensable 
to support the conclusion that the relationship 
between the intestinal microbiota and an altered 
Figure 4. Integrated omics/systems biology/animal model approach to elucidate host-microbiota interactions in inflammation. 
Combining the results of the gnotobiotic and the metabolite- based approaches yields a set of bacteria capable of causally effecting 
an immune phenotype by potentially distinct mechanisms. These strains may be used together as rationally designed microbial 
therapeutics.
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immune homeostasis is a means by which the 
microbiota impacts NCDs.
A variety of computational tools for the integra-
tion of multi-omics data is available.7 A recent 
devised computational approach, entailing the 
iterative coverage-based read assignment (ICRA) 
algorithm and the structural genomic variant finder 
(SGV-Finder), has been used to systematically 
identify microbial genomic structural variants 
across metagenomic samples of 887 healthy sub-
jects. The ICRA algorithm resolves ambiguous read 
assignments to regions that are similar between 
different bacteria, after which the SGV-Finder sys-
tematically characterizes structural variation across 
ICRA-corrected reads in the healthy human micro-
biome. This approach enabled identification of SV- 
harbored genes with distinct functions associated 
with bacterial growth rates, as well as associations 
between SVs and host disease risk factors. For 
instance, SV-clustered genes in Anaerostipes hadrus 
encoded a composite inositol catabolism-butyrate 
biosynthesis pathway, the presence of which is 
associated with lower host metabolic disease risk. 
Overall, this novel computational modality exposes 
a new facet of the microbiome that aids in mechan-
istically understanding host–microbe interactions.8
One common bottom-up systems biology 
approach that enables data integration is con-
straint-based reconstruction and analysis 
(COBRA). COBRA relies on manually curated gen-
ome-scale reconstructions of the target organism 
that can readily be contextualized with omics data, 
e.g., transcriptomic or metabolomic data.10 
Genome-scale reconstructions have been built for 
a number of organisms including human,11 
mouse,12 rat,13 and 818 strains inhabiting the 
human gut.14,124 The latter resource, deemed 
AGORA, has been curated based on refined gen-
ome annotation and data from biochemical experi-
ments and thus enables interrogating the 
metabolite biosynthetic capabilities of individual 
bacterial strains in the gut.124 By contextualizing 
AGORA with 16S rRNA or shotgun metagenomic 
data, the metabolic potential of a given microbiome 
can be mechanistically modeled.124 Such multi- 
species modeling approaches were applied to inves-
tigating host-microbe interactions linked to sulfide 
production in colorectal cancer,16 modeling the 
lung microbiome in Cystic Fibrosis patients,19 
predicting dietary supplements that SCFAs produc-
tion in Crohn’s Disease patients147 and analyzing 
microbial network patterns in relapsing Crohn’s 
Disease.148 In a recent study, the BA transformation 
potential of the microbiomes of Crohn’s Disease 
patients and healthy controls has been predicted 
and found to be distinct in the Crohn’s Disease 
microbiomes.149 In a follow-up effort, the metabo-
lome of the same microbiomes was systematically 
predicted and also found to differ between dysbiotic 
and control microbiomes.150 The predicted meta-
bolite fluxes have also been linked to the synthesiz-
ing strains and compared with published 
metabolomics data from the same cohort.150 Thus, 
these computational models can lead to mechan-
istic hypotheses linking altered bacteria to metabo-
lites in NCD states.151
Software tools152 have been developed that 
enable deriving condition-and tissue-specific 
human cell models, e.g., of immune cells, from the 
human reconstruction,153 which could be subse-
quently integrated into microbiome modeling. 
That way, the effect of microbial metabolism on 
the host immune system could be interrogated spe-
cifically. Moreover, a whole-body model of human 
metabolism is available, which has been integrated 
with contextualized microbiome models resulting 
in personalized human-microbiome models.154 
Candidate metabolites and relevant producer bac-
teria for a given immunomodulatory phenotype 
can be validated later by, for example, gnotobiotic 
or metabolic engineering studies to identify the 
functionally redundant group of commensal 
organisms.
Conclusion
Research of the last decades indicated that metabo-
lites secreted by the intestinal microbiota are unde-
niably involved physiological processes that are key 
for human health. Alteration in these bacterial 
metabolites during dysbiosis contributes to the 
downstream modulation of host immune homeos-
tasis and chronic inflammation, a resemblance 
point in most NCDs. Therefore, identification of 
the bacterial metabolites that are involved in mod-
ulating the host immune response and the mechan-
ism behind the modulation opens the door to the 
development of targeted microbial therapeutics 
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efficacy via as-of-yet undiscovered mechanisms. 
The systems biology cycle of alternating experi-
mental and computational approaches4 will be an 
indispensable tool for the elucidation of such 
mechanisms. Namely, an approach combining 
omics data generated from cohort studies, systems 
biology models, and in vitro (culture based) and 
animal models could lead to the identification of 
such mechanisms. For example, metabolic models 
could be contextualized with omics data and used 
to predict mechanisms for potential host- 
microbiome-disease interactions. These mechan-
isms could then be validated in in vitro and animal 
experiments.
Combination of metabolomics with other - 
omics, bioinformatics, and systems biology 
approaches allow us to cope with most of the 
complications described in the present article, 
and gives clinically and pharmacologically mean-
ingful outcomes. For example, trans-omics strat-
egy helps pharmaceutical research to look at this 
field as a challenging and exciting path to treat 
disease such as NCDs. It has been suggested that 
therapeutic and dietary interventions should be 
patient-specific.155 By integrating omics data 
with pharmacokinetic and metabolic modeling, 
personalized models could be created, which 
could lead to the prediction of such patient- 
specific drug- and dietary interventions and sub-
sequent validation.
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